000950.SZ
重药控股
SZSE · Healthcare · F 批发零售 · CN
CNY 5.41
−1.28%Year over year
Reported trailing growth
- Revenue
- +0.9%
- EBITDA
- —
- EBIT
- +18.2%
- EPS
- +41.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.7%
- EBITDA
- -15.7%
- EBIT
- -21.9%
- Net income
- -25.9%
- EPS
- -26.3%
- Free cash flow
- +194.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026